Please login to the form below
Roivant
This page shows the latest Roivant news and features for those working in and with pharma, biotech and healthcare.
Pfizer and Roivant form new company to develop inflammatory disease drug
Pfizer and Roivant Sciences have launched a new company focused on developing RVT-3101, a fully human monoclonal antibody targeting TL1A, for inflammatory and fibrotic diseases. ... Mayukh Sukhatme, president and chief investment officer of Roivant, said:
Latest news
-
Myovant preps US filing for relugolix in prostate cancer
companies in the Roivant Sciences group headed by entrepreneur Vivek Ramaswamy – in September.
-
Sumitomo Dainippon goes big on biotech with $3bn Roivant deal
The five companies Sumitomo is set to take over from Roivant include Myovant, Urovant, Enzyvant, Altavant and another undisclosed spinout company. ... in this alliance,” said Vivek Ramaswamy, founder and chief executive officer of Roivant.
-
Myovant has second phase 3 trial to back its uterine fibroids drug
The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, says the LIBERTY 2 trial showed a 71.2% response rate for once-daily relugolix in women with uterine
-
Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease
Roivant Sciences subsidiary Metavant licensed US and European rights to the drug last year for $35m upfront, a $15m equity investment and up to $500m in milestone payments.
-
Myovant’s fibroids drug clears phase 3 trial, but shares sink
The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, reported that 73% of women with uterine fibroids and heavy menstrual bleeding who were treated with relugolix responded to
More from news
Approximately 8 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Pharma deals in May 2015
110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in behavioural and neuropsychiatric disturbances.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- EU outlines measures to mitigate antibiotic shortage across Europe
- Europe’s cancer community publishes new report on transforming patient care
- Meeting healthcare’s rising challenges
- Diversifying Healthcare AI with Federated Learning
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
